Propanc Biopharma, Inc.

Latest News

Jul 15, 2019

Propanc Biopharma Provides Update on Preparation of PRP for Clinical Trial Application Submission and Recently Completed Reverse Stock Split

MELBOURNE, Australia--(BUSINESS WIRE)-- Propanc Biopharma, Inc. (OTC: PPCBD) (“Propanc”), a biopharmaceutical company developing new cancer treatments for patients suffering from recurring and metastatic…

View All Press Releases

Jun 27, 2019

Propanc Biopharma’s Intellectual Property Portfolio Undergoes Rapid Growth

Jun 24, 2019

Propanc Biopharma Appoints Carlo Campiciano as Chief Financial Officer

May 6, 2019

Propanc Biopharma Appoints Dr. Ralf Brandt to its Scientific Advisory Board
Latest Publication Antitumour efficacy of chymotrypsinogen and trypsinogen View All Publications
In vitro treatment of carcinoma cell lines with pancreatic (pro)enzymes suppresses the EMT programme and promotes cell differentiation
A formulation of pancreatic pro-enzymes provides potent anti-tumour efficacy: a pilot study focused on pancreatic and ovarian cancer